Angiotensin II AT2 receptors are produced locally in nociceptive tissues [REF].
Animal studies, five Phase I clinical trials, unpublished data at Spinifex Pharmaceuticals, implicated a dose range of 10-50 mg per day of EMA401 to be effective on human beings.